First AD

Second AD

Prostate Cancer

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Recent Advances in the Treatment of Prostate Cancer 

Peer Exchange

Reflections on results of the VISION trial, which utilized 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Results of the VISION Trial and Real-World Use of 177Lu-PSMA-617 in mCRPC

Overview of Improvements in Prostate Cancer Management

Optimizing Use of PSMA PET Imaging and PSADT in Prostate Cancer

Evolving Treatment Landscape of Nonmetastatic CRPC 

Factors in Selecting Novel AR-Targeted Therapy for Nonmetastatic CRPC

Nonmetastatic Castration-Resistant Prostate Cancer: Quality of Life Measures

Monitoring Strategies in Nonmetastatic CRPC

Overview of Treatment for Metastatic HSPC

Role of Micronized Abiraterone in Metastatic HSPC

Selecting Optimal Therapy for mHSPC: Design of the ARASENS Trial

Interpreting Data From the ARASENS Trial in Metastatic HSPC

Overview of Therapy for mCRPC: PARP Inhibitors

DNA Alterations and Selection of PARP Inhibitors in mCRPC

Metastatic CRPC: Utility of Imaging as a Biomarker

Selecting Among Novel Imaging Options in Metastatic CRPC

Role of 177Lu-PSMA-617 in mCRPC and Bone Metastases 

Addressing Bone and Visceral Metastases in Metastatic CRPC

Prostate Cancer Management: Future Directions in Care 